Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma.
PMID 19789534 · PMC2768081 · British journal of cancer · 2009 · 8 claims · 7 setups
Cathepsin D, identified via comparative 2D PAGE of conditioned media from RCC cell lines vs normal renal cultures, is a candidate secreted biomarker of RCC
-
Full-text index only
Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis.
PMID 15953868 · PMC2782202 · Journal of Korean medical science · 2005 · 6 claims · 4 setups
Eight proteins from 11 differentially expressed spots were identified in conventional RCC versus normal kidney tissue by 2D-PAGE and MALDI-TOF-MS
-
Full-text index only
Pathway analysis of kidney cancer using proteomics and metabolic profiling.
PMID 17123452 · PMC1665458 · Molecular cancer · 2006 · 8 claims · 8 setups
31 proteins are differentially expressed with high statistical significance (p<0.05) in ccRCC tumor tissue compared to adjacent non-malignant kidney tissue
-
Full-text index only
CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.
PMID 16892042 · PMC2360640 · British journal of cancer · 2006 · 6 claims · 6 setups
CD70 was identified by proteomic analysis of plasma membrane preparations as highly expressed in A498 and SW839 RCC-derived cell lines
-
Full-text index only
Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers.
PMID 15502247 · PMC3839398 · Disease markers · 2004 · 8 claims · 8 setups
Proteomics approaches (2D Western blot, protein microarray, multiplex ELISA) can identify tumor antigen-directed autoantibodies as candidate cancer biomarkers